Fig. 4. Gossypol acetate reduced mHTT level and rescued HD
relevant phenotypes in full-length-HTT-128Q and HTTexon1-72Q transgenic
flies.
Quantification of HTT levels in transgenic fly head by HTRF
measurements (using the 2B7/MW1 antibody pair). TransgenicDrosophila with elav-GAL4 driven expression of human
full-lengthHTT-16Q (Full-Htt-16Q), Full-HTT-128Q (Full-Htt-128Q),
HTTexon1-25Q (Exon1-HTT-25Q), or HTTexon1-72Q (Exon1-HTT-72Q) were fed
with 10μM gossypol acetate or DMSO for 2 weeks. Statistical analysis
was performed by two-way ANOVA test *, P<0.05, **,
P<0.01 ***,P<0.001.
(B) Gossypol acetate treatment rescued the motor behavior deficits in in
transgenic mHTT Drosophila with indicated genotypes. Flies were fed with
10μM gossypol acetate or DMSO (black lines) for 2 weeks, respectively.
The statistics were performed by two-way ANOVA test. ***,
P<0.001; ns, no significance.
(C) As in B, but using flies expressing HTT-exon1 fragments with
indicated Q lengths. The statistics were performed by two-way ANOVA
test. ***, P<0.001; ns, no significance.
(D) Survival curves of flies with indicated transgene and compound
treatment. Flies were fed with 10μM gossypol acetate (red lines) or DMSO
(black lines) for 2 weeks, respectively. The statistics were performed
by the log-rank test. ***, P<0.001; ns, no significance.
For all panels, bars represent mean and s.d.